Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Lymphoma, Non-Hodgkin 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Sezary Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 11Cisplatin 8pembrolizumab 2Oxaliplatin 2Nivolumab 2Docetaxel 2Capecitabine 2trametinib 1titanium silicide 1telotristat ethyl 1sovateltide 1niraparib 1milademetan 1folfirinox 1dostarlimab 1devimistat 1cytokine inducible SH2-containing protein 1brigimadlin 1bintrafusp alfa protein, human 1becatecarin 1adagrasib 1Sorafenib 1S 1 (combination) 1Pancreaticojejunostomy 1NUC-1031 1Leucovorin 1Hydroxychloroquine 1Fluorouracil 1Cetuximab 1Catheter Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Biliary Tract Neoplasms × devimistat × Clear all
NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

University of Michigan Rogel Cancer Center

Phase 1/2 Terminated
75 enrolled 17 charts
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡